Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 23, 2026

Top Wide-Moat Stocks to Invest in for Long-term Growth

View original at finance.yahoo.com
Top Wide-Moat Stocks to Invest in for Long-term Growth An updated edition of the January 5, 2026 article. A wide moat refers to companies with lasting competitive advantages that protect them from rivals, similar to how a moat defends a castle…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The generative AI revolution continues to be a tailwind for NVIDIA

    80% confidence
  • Datacenter presents a solid growth opportunity for NVIDIA as businesses are increasingly shifting toward cloud

    80% confidence
  • Lam Research has high exposure to the memory segment, which is likely to see tremendous growth in the long run

    80% confidence
  • Moody's dominant position in the credit rating industry, along with opportunistic acquisitions and restructuring efforts to diversify revenues and footprint, supports top-line expansion

    80% confidence
  • NVIDIA is rapidly gaining traction in enterprise AI, expanding its market beyond cloud providers

    80% confidence
  • Technology inflections in the semiconductor industry, including 3D device scaling, multiple patterning, process flow, and advanced packaging chip integration, are expected to continue driving sustainable growth and increasing Lam Research's served market

    80% confidence
  • ASML is well-positioned to capitalize on the AI revolution, which is driving massive demand for advanced semiconductors

    80% confidence
  • With AI applications requiring more efficient and high-speed memory, high-bandwidth memory adoption is accelerating

    80% confidence
  • ASML's High-NA EUV technology represents the next frontier in chip manufacturing designed for sub-2nm nodes

    80% confidence
  • AI adoption is spreading beyond cloud hyperscalers, with industries such as healthcare, automotive, and robotics increasingly investing in AI-powered solutions

    80% confidence
  • ASML maintains a near-monopoly on extreme ultraviolet (EUV) lithography, which is essential for producing advanced chips at 3nm and below

    80% confidence
  • Wide-moat companies typically derive their advantage from factors such as strong brand recognition, network effects, high customer switching costs, regulatory hurdles and economies of scale

    80% confidence
  • Lam Research is at the center of the AI revolution, with its advanced fabrication tools playing a crucial role in enabling high-performance computing

    80% confidence
  • Investing in wide-moat companies provides a solid strategy for building long-term wealth, as these businesses typically produce steady cash flows and deliver shareholder value through dividend payments and stock price growth

    80% confidence
  • The semiconductor memory market is being driven by the growing proliferation of artificial intelligence (AI), Machine Learning, Blockchain, cloud computing, big data, mobile devices and the Internet of Things

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com